Committee reviews a wave of signed bills affecting pharmacy practice, urges outreach and interagency coordination
Loading...
Summary
The Enforcement & Compounding Committee reviewed multiple recently chaptered bills affecting pharmacist authorities, confidentiality and payment protections, and urged the board to broaden outreach and coordinate with other agencies.
At its Oct. 16 meeting the Enforcement & Compounding Committee reviewed a package of recently chaptered bills and discussed outreach and implementation steps the board should take.
Key enacted measures discussed included:
- AB 82 (ch. 2025): Expands address confidentiality protections for health-care workers (including those providing gender-affirming care) and prohibits reporting certain prescriptions (testosterone, mifepristone) to the DOJ CURES contractor in specified circumstances. Members urged broad dissemination to affected providers.
- AB 144 (ch. 2025): Authorizes pharmacists to independently initiate and administer immunizations that have an ACIP recommendation or are recommended by the California Department of Public Health as of Jan. 1, 2025. Staff issued a pharmacy alert on Sept. 18 and members agreed to coordinate implementation guidance.
- AB 260 (ch. 2025): Protects confidentiality of reproductive-health-related treatment; members noted the statute—s importance amid changing care access.
- AB 309 (ch. 2025): Changes authority around furnishing hypodermic needles and syringes; members observed that AB 1503 broadens pharmacist furnishing authority, increasing opportunity for harm-reduction services.
- SB 40 (ch. 2025): Imposes insulin cost limits; members requested the staff—s implementation outreach also flag related federal executive actions that affect federally qualified health centers.
- SB 41 (ch. 2025): Strengthens regulation of pharmacy benefit managers (PBMs); members urged coordination with the Department of Managed Health Care for implementation and public education.
The committee also reviewed bills that were vetoed after the agenda was posted (for example, AB 742, SB 418 and SB 641) and noted which implementation activities were no longer applicable.
Public commenters, including representatives of the California Pharmacists Association, offered support for the board—s education plans and offered to collaborate on dissemination and training. Members emphasized the volume of change and asked staff to consolidate and update FAQs, website materials and other outreach so the regulated public can operationalize the new laws.
